Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Therapy01:28

Drug Therapy

322
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
322
Direct-Acting Cholinergic Agonists: Pharmacokinetics01:31

Direct-Acting Cholinergic Agonists: Pharmacokinetics

2.0K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
2.0K
Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

1.1K
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
1.1K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

232
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
232
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

3.2K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
3.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sub-RDT Plasmodium vivax infections and G6PD deficiency in Kayin State, Myanmar.

Malaria journal·2026
Same author

Altered Pharmacokinetics and Delayed Sputum Conversion in Tuberculosis Patients Co-Infected With HIV.

Tropical medicine & international health : TM & IH·2026
Same author

Methylene blue retains in vitro activity against early ring-stage artemisinin-resistant Plasmodium falciparum.

Malaria journal·2026
Same author

A sustainable house design to improve child health in rural Africa: a cluster-randomized controlled trial.

Nature medicine·2026
Same author

Changing genetic profiles of <i>Plasmodium falciparum</i> piperaquine resistance in Southeast Asia over 25 years.

Antimicrobial agents and chemotherapy·2026
Same author

<i>Plasmodium vivax</i> Malaria Relapse Risk Depends on Transmission Intensity: Evidence From a Longitudinal Study in Northwest Thailand.

Open forum infectious diseases·2026
Same journal

Genotypic analysis of Plasmodium falciparum malaria parasites in a clinical trial of RTS,S vaccination in combination with seasonal malaria chemoprevention.

Malaria journal·2026
Same journal

Less is more: modelling the impact of species-targeted versus broadcast larviciding in Anopheles funestus-dominated malaria transmission settings.

Malaria journal·2026
Same journal

'Poverty is the biggest barrier': stakeholder perspectives on social determinants of malaria in Wakiso District, Uganda.

Malaria journal·2026
Same journal

Clinical malaria recurrence and associated factors in infancy following IPTp-DP versus IPTp-SP in Busia, Uganda; a secondary analysis using the Conditional Frailty model.

Malaria journal·2026
Same journal

Prevalence of molecular markers related to artemisinin partial resistance and ACT partner drug resistance in the Plasmodium falciparum population in Kongo Central, DRC.

Malaria journal·2026
Same journal

Malaria among febrile patients during a yellow fever outbreak in Ghana: a cross-sectional study.

Malaria journal·2026
See all related articles

Related Experiment Video

Updated: Feb 26, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.4K

Challenges to replace ACT as first-line drug.

Aung Pyae Phyo1, Lorenz von Seidlein2

  • 1Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot, Thailand.

Malaria Journal
|July 26, 2017
PubMed
Summary
This summary is machine-generated.

Artemisinin resistance necessitates new malaria treatments. Combining existing drugs like artemether-amodiaquine offers a potential interim solution while new therapies are evaluated.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.9K
Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

5.5K

Related Experiment Videos

Last Updated: Feb 26, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.4K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.9K
Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

5.5K

Area of Science:

  • Malariology
  • Infectious Diseases
  • Pharmacology

Background:

  • Artemisinin resistance is spreading in Asia, requiring changes to first-line malaria therapy.
  • Reliance on sequential drug regimen replacement may be insufficient due to emerging resistance and safety concerns with new candidates.
  • Several promising antimalarial drugs face challenges including safety issues and potential for rapid resistance development.

Purpose of the Study:

  • To evaluate the challenges and potential strategies for managing artemisinin resistance in malaria treatment.
  • To explore the viability of combining existing antimalarial drugs as a temporary measure against resistant Plasmodium falciparum strains.

Main Methods:

  • Review of current antimalarial drug development pipeline and resistance trends.
  • Analysis of empirical and trial-based combination therapies for malaria.
  • Assessment of safety and efficacy concerns for novel antimalarial agents.

Main Results:

  • New antimalarial drug candidates (e.g., KAE 609, KAF 156) show potential but also raise safety and resistance concerns.
  • Combining licensed antimalarials, such as dihydroartemisinin-piperaquine with mefloquine or co-artemether with amodiaquine, is being explored empirically and in trials.
  • These combination strategies are considered a promising stop-gap measure against artemisinin-resistant malaria.

Conclusions:

  • The emergence of artemisinin resistance requires innovative treatment strategies beyond simple drug replacement.
  • Combining already licensed antimalarials presents a viable interim solution for treating resistant malaria.
  • Ongoing trials will determine the long-term efficacy and safety of these combination regimens.